161 related articles for article (PubMed ID: 32605908)
21. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
22. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.
Raimondi A; Colombo F; Pintarelli G; Morosi C; Renne SL; Frezza AM; Saponara M; Dei Tos AP; Mazzocchi A; Provenzano S; Casali PG; Stacchiotti S
Anticancer Drugs; 2018 Jul; 29(6):589-595. PubMed ID: 29668485
[TBL] [Abstract][Full Text] [Related]
23. RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH LITERATURE REVIEW.
Damirov F; Menge F; Hohenberger P
Georgian Med News; 2022 Nov; (332):56-59. PubMed ID: 36701777
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
25. Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).
Machado I; Cruz J; Lavernia J; Rayon JM; Poveda A; Llombart-Bosch A
Int J Surg Pathol; 2017 Sep; 25(6):543-549. PubMed ID: 28459168
[TBL] [Abstract][Full Text] [Related]
26. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
28. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
Schuetze SM; Zhao L; Chugh R; Thomas DG; Lucas DR; Metko G; Zalupski MM; Baker LH
Eur J Cancer; 2012 Jun; 48(9):1347-53. PubMed ID: 22525224
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
31. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
32. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
ElNaggar AC; Hays JL; Chen JL
PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
[TBL] [Abstract][Full Text] [Related]
33. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
[TBL] [Abstract][Full Text] [Related]
34. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa S; Bui NQ; Ganjoo KN
Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
[TBL] [Abstract][Full Text] [Related]
36. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Martin-Liberal J; Tirado OM; García del Muro X
Expert Rev Anticancer Ther; 2015 Mar; 15(3):257-9. PubMed ID: 25586480
[TBL] [Abstract][Full Text] [Related]
38. mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success.
Szymanowski M; Estebanez MS; Padidela R; Han B; Mosinska K; Stevens A; Damaj L; Pihan-Le Bars F; Lascouts E; Reynaud R; Ferreira C; Bansept C; de Lonlay P; Saint-Martin C; Dunne MJ; Banerjee I; Arnoux JB
J Clin Endocrinol Metab; 2016 Dec; 101(12):4719-4729. PubMed ID: 27691052
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Yi Z; Liu B; Sun X; Rong G; Wang W; Li H; Guan X; Li L; Zhai J; Li C; Qian H; Ma F; Xu B
Breast; 2020 Aug; 52():17-22. PubMed ID: 32335491
[TBL] [Abstract][Full Text] [Related]
40. [BOLERO -- another remarkable step in treatment of breast cancer].
Rubovszky G; Láng I
Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]